comparemela.com

Latest Breaking News On - John valliant - Page 2 : comparemela.com

AstraZeneca to Acquire Fusion Pharmaceuticals, for Up To $2.4 Billion

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Canada
John-valliant
Nasdaq
Fusion-pharmaceuticals-inc
Fusion-pharmaceuticals
Astrazeneca
Chief-executive-officer

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
Amanda-cray
John-valliant
Prnewswire-fusion-pharmaceuticals-inc
Investor-relations-corporate-communications
Healthcare-life-sciences-conference
Nasdaq
Niowave-inc
Astrazeneca
Fusion-pharmaceuticals

Area bibliophiles on what they loved in 2023 and what to read in 2024

Area bibliophiles on what they loved in 2023 and what to read in 2024
ideastream.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ideastream.org Daily Mail and Mail on Sunday newspapers.

Switzerland
United-states
America
American
Swiss
Samantha-chang
James-mcbride
Wendy-bartlett
Lan-samantha-chang
Jamie-kaufman
Rebecca-yarros
Ross-gay

Shares of Fusion Pharmaceuticals Rise 7.8% With Study Protocol Aligment Reached

By Ben Glickman Shares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators. The stock was up 7.8% to $9.10,. -January 04, 2024 at 06:39 pm EST - MarketScreener

John-valliant
Ben-glickman
Fusion-pharmaceuticals
Drug-administration
Executive-john-valliant
Dow-jones
Markets

Fusion Pharmaceuticals provides manufacturing update - Canadian Manufacturing

Fusion reported on Jan. 4 that it has completed validation of its good manufacturing practice (GMP) manufacturing facility and produced the first clinical dose of a TAT.

Boston
Massachusetts
United-states
John-valliant
Fusion-pharmaceuticals-inc
Drug-administration
Chief-executive-officer-john-valliant

vimarsana © 2020. All Rights Reserved.